Explanatory Note
Emerald Health Pharmaceuticals Inc. has prepared this Form 1-A POS solely for the purpose of filing Exhibit 6.13 and Exhibit 6.14.
Part III – EXHIBITS
Item 16. Exhibits
(a) Exhibits.
III-1
† | Filed herewith. |
# | Previously filed. |
## | Filed as an exhibit to the Emerald Health Pharmaceuticals Inc. Semiannual Report on Form 1-SA filed with the SEC on September 30, 2019 and incorporated herein by reference. |
+ | Filed as an exhibit to the Emerald Health Pharmaceuticals Inc. Current Report on Form 1-U filed with the SEC on November 21, 2019 and incorporated herein by reference. |
++ | Filed as an exhibit to the Emerald Health Pharmaceuticals Inc. Current Report on Form 1-U filed with the SEC on December 9, 2019 and incorporated herein by reference. |
^ | Filed as an exhibit to the Emerald Health Pharmaceuticals Inc. Annual Report on Form 1-K filed with the SEC on April 28, 2020 and incorporated herein by reference. |
* | Portions of this exhibit containing confidential information have been omitted pursuant to a request for confidential treatment filed with the SEC pursuant to Rule 406 under the Securities Act. Confidential information has been omitted from the exhibit in places marked “[*****]” and has been filed separately with the SEC. |
III-2
Pursuant to the requirements of Regulation A+, the issuer certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form 1-A this Post-Qualification Amendment No. 4 and has duly caused this offering statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on July 10, 2020.
Emerald Health Pharmaceuticals Inc. | |||
By: | /s/ James M. DeMesa | ||
Name: | James M. DeMesa, M.D. | ||
Title: | Chief Executive Officer |
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints James M. DeMesa, M.D. and Lisa Sanford, or any of them, his true and lawful attorney-in-fact and agent, with full power of substitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments to this Form 1-A offering statement, and to file the same with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and ratifying and confirming all that said attorney-in-fact and agent or his substitute or substitutes may lawfully do or cause to be done by virtue hereof.
This offering statement has been signed by the following persons in the capacities and on the dates indicated.
/s/ James M. DeMesa | Date: July 10, 2020 | |
Name: James M. DeMesa, M.D. Title: President, Director and Chief Executive Officer | ||
/s/ Lisa C. Sanford | Date: July 10, 2020 | |
Name: Lisa C. Sanford Title: Chief Financial Officer | ||
/s/ James L. Heppell | Date: July 10, 2020 | |
Name: James L. Heppell, LLB Title: Director and Chairman of the Board | ||
/s/ Gaetano A. Morello | Date: July 10, 2020 | |
Name: Gaetano A. Morello, ND Title: Director | ||
/s/ Punit S. Dhillon | Date: July 10, 2020 | |
Name: Punit S. Dhillon Title: Director |
III-3